12 Health Care Stocks Moving In Wednesday’s Pre-Market Session
Gainers Aptorum Gr (NASDAQ:APM) shares increased by 199.0% to $8.64 during Wednesday’s pre-market session. The company’s market cap…
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers Evelo Biosciences (NASDAQ:EVLO) shares rose 138.7% to $0.24 during Thursday’s regular session. Trading volume for this security…
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Gainers
Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its EDP1815 Phase 2 trial, in which the primary endpoint was not met.
Nexcella, An Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context Of U.S. Food And Drug Administration Approved BCMA CAR T Cells
Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (NASDAQ:IMMX) ("ImmixBio", "Company", "We" or "Us") today announced that an editorial written by Maria Sjöstrand and
Nexcella, A Subsidiary Of Immix Biopharma, Presents 42-Patient Interim Data, With 90% Overall Response Rate In Relapsed Or Refractory Multiple Myeloma At NXC-201 Therapeutic Dose From Its Phase 1 Expansion Trial At The 5th European Car T-Cell Meeting
The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated with NXC-201 (formerly HBI0101), of which 29 received the therapeutic dose of 800 million CAR+T cells as of the
EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In January: Where Do SPY, Tesla, Apple And Ford Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
ImmixBio Ships Tislelizumab For Patient Dosing In Its Combination Clinical Trial With IMX-110 In Advanced Solid Tumors
Tislelizumab supplied by BeiGene as part of ImmixBio's Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid Tumors
IMX-110 + Tislelizumab clinical trial
Dow Drops Over 300 Points After Fed Raises Key Overnight Interest Rate By 50 bps
U.S. stocks turned lower toward the end of trading, after the Federal Reserve announced its policy decision.